Latest News and Press Releases

SUNRISE-PD Phase 2 trial of AXO-LENTI-PD for Parkinson's disease continues to enroll patients in second dose cohort with data expected in the fourth quarter of calendar 2019Data from patients dosed...

-David Nassif joins executive management team as CFO, effective July 1, 2019- -Senthil Sundaram to join Axovant’s Board of Directors- BASEL, Switzerland, July 01, 2019 (GLOBE NEWSWIRE) -- Axovant...

-Details from ongoing SUNRISE-PD Phase 2 trial of AXO-Lenti-PD and AXO-AAV-GM2 program highlighted in poster presentations- BASEL, Switzerland, June 24, 2019 (GLOBE NEWSWIRE) -- Axovant Gene...

BASEL, Switzerland and CORBEIL-ESSONNES, France, June 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies, today...

Established diversified pipeline of three clinical-stage gene therapy programs for serious neurological disorders including Parkinson’s disease, GM1 gangliosidosis, and Tay-Sachs  SUNRISE-PD Phase 2...

AXO-Lenti-PD was observed to be generally well tolerated at six months, and continued to demonstrate benefits in both patients across multiple measures after a single administrationTotality of data...

BASEL, Switzerland, May 31, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...

BASEL, Switzerland, May 20, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing innovative gene therapies, today announced that Pavan Cheruvu,...

- Milestone marks the first patient with GM1 gangliosidosis treated with gene therapy- -Initial data expected in second half of 2019- -AXO-AAV-GM1 is Axovant’s third investigational gene therapy...

Shares to begin trading on split-adjusted basis on May 8, 2019 BASEL, Switzerland, May 07, 2019 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT), a clinical-stage company developing...